Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1)

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 62-72

  Xu, Hui ^a  

^a NORTHWEST A F UNIVERSITY   (China)

Author keywords

Acquired immunodeficiency syndrome; Bis(heteroaryl)piperazine; Human immunodeficiency virus type 1; Non nucleoside reverse transcriptase inhibitor; Structure activity relationship.; Synthesis

Indexed keywords

(ALKYLAMINO)PIPERIDINE BIS(HETEROARYL)PIPERAZINE DERIVATIVE; ABACAVIR; BIS(HETEROARYL)PIPERAZINE DERIVATIVE; DELAVIRDINE; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE;

DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; DELAVIRDINE; DRUG DESIGN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PIPERAZINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77951136077     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791112578     Document Type: Review

References (41)

1. Lawn, S.D. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J. Infect. Dis., 2004, 48, 1-12.
2. UNAIDS, Report on the global HIV/AIDS epidemic in 2007.
3. UNAIDS, Report on the global HIV/AIDS epidemic in 2006.
4. Ho, D.D.; Bieniasz, P.D. HIV-1 at 25. Cell, 2008, 133, 561-565
5. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272, 872-877
6. Vaishnav, U.N.; Wong-Staal, F. The biochemistry of AIDS. Annu. Rev. Biochem., 1991, 60, 577-630.
7. Mitsuya, H.; Yarchoan, R.; Broder, S. Molecular targets for AIDS therapy. Science, 1990, 249, 1533-1544
8. De Clercq, E. New developments in anti-HIV chemotherapy. Biochim. Biophy. Acta, 2002, 1587, 258-275
9. Johnston, M.I.; Hoth, D.F. Present status and future prospects for HIV therapies. Science, 1993, 260, 1286-1293
10. Condra, J.H.; Schleif, W.A.; Blahy, O.M.; Gabryelski, L.J.; Graham, D.J.; Quintero, J.C.; Rhodes, A.; Robbins, H.L.; Roth, E.; Shivaprakash, M.; Titus, D.; Yang, T.; Teppler, H.; Squires, K.E.; Deutsch, P.J.; Emini, E.A. In-vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature, 1995, 374, 569-571
11. Merluzzi, V.J.; Hargrave, K.D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J.C.; Shih, C.D.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A.S.; Faakes, R.; Eckner, R.J.; Koup, R.A.; Sullivan, J.L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science, 1990, 250, 1411-1413
12. McBurney, S.P.; Ross, T.M. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr. Pharm. Des., 2006, 12, 2031-2055
13. Kaiser, J. Aids research-review of vaccine failure prompts a return to basics. Science, 2008, 320, 30-31
14. Cohen, J. Retrovirus meeting-back-to-basics push as HIV prevention struggles. Science, 2008, 319, 888.
15. Bourinbaiar, A.S. HIV drug design. Curr. Pharm. Des., 2006, 12, 1941-1942
16. Veljkovic, V.; Veljkovic, N.; Este, J.A.; Huther, A.; Dietrich, U. Application of the EIIP/ISM bioinformatics concept in development of new drugs. Curr. Med. Chem., 2007, 14, 441-453
17. Pettersson, S.; Clotet-Codina, I.; Este, J.A.; Borrell, J.I.; Teixido, J. Recent advances in combinatorial chemistry applied to development of anti-HIV drugs. Mini-Rev. Med. Chem., 2006, 6, 91-108.
18. Agrawal. L.; Lu, X.; Jin, Q.; Alkhatib, G. Anti-HIV therapy: current and future directions. Curr. Pharm. Des., 2006, 12, 2031-2055
19. Siegert, S.; Schnierle, P.; Schnierle, B.S. Novel anti-viral therapy: drugs that block HIV entry at different target sites. Mini-Rev. Med. Chem., 2006, 6, 557-562
20. Reiche, E.M.V.; Bonametti, A.M.; Voltarelli, J.C.; Morimoto, H.K.; Watanabe, M.A.E. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr. Med. Chem., 2007, 14, 1325-1334
21. Richter, S.N.; Frasson, I.; Palu, G. Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy? Curr. Med. Chem., 2009, 16, 267-286
22. Sluis-Cremer, N.; Ross, T. HIV-1 reverse transcriptase inhibitors: drug resistance and drug development. Curr. Pharm. Des., 2006, 12, 1809-1810
23. Martins, S.; Ramos, M.J.; Fernandes, P.A. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr. Med. Chem., 2008, 15, 1083-1095
24. Deng, J.; Dayam, R.; Al-Mawsawi, L.Q.; Neamati, N. Design of second generation HIV-1 integrase inhibitors. Curr. Pharm. Des., 2007, 13, 129-141
25. Zhao, G.S.; Wang, C.; Liu, C.; Lou, H.X. New developments in diketo-containing inhibitors of HIV-1 integrase. Mini-Rev. Med. Chem., 2007, 7, 707-725.
26. Yu, F.; Liu, X.Y.; Zhan, P.; De Clercq, E. Recent advances in the research of HIV-1 RNase H inhibitors. Mini-Rev. Med. Chem., 2008, 8, 1243-1251
27. Busso, M.; Mian, A.M.; Hahn, E.F.; Resnick, L. Nucleotide dimers suppress HIV expression in vitro. AIDS Res. Hum. Retrovirus, 1988, 4, 449-455
28. McQuade, T.J.; Tomasselli, A.G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T.K.; Heinrikson, R.L.; Tarpley, W.G. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science, 1990, 4941, 454-456
29. Romero, D.L.; Busso, M.; Tan, C.K.; Reusser, F.; Palmer, J.R.; Poppe, S.M.; Aristoff, P.A.; Downey, K.M.; So, A.G.; Resnick, L.; Tarpley, W.G. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA, 1991, 88, 8806-8810
30. Romero, D.L.; Morge, R.A.; Genin, M.J.; Biles, C.; Busso, M.; Resnick, L.; Althaus, I.W.; Reusser, F.; Thomas, R.C.; Tarpley, W.G. Bis(heteroaryl) piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino] -pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem., 1993, 36, 1505-1508
31. Romero, D.L.; Morge, R.A.; Biles, C.; Berriospena, T.N.; May, P.D.; Palmer, J.R.; Johnson, P.D.; Smith, H.W.; Busso, M.; Tan, C.K.; Voorman, R.L.; Reusser, F.; Althaus, I.W.; Downey, K.M.; So, A.G.; Resnick, L.; Tarpley, W.G.; Aristoff, P.A. Discovery, synthesis, and bioactivity of bis(heteroaryl) piperazines 1. a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 1994, 37, 999-1014.
32. Genin, M.J.; Chidester, C.G.; Rohrer, D.C.; Romero, D.L. Design and synthesis of a conformationally constrained analog of the bis(heteroaryl) piperazine (BHAP) HIV-1 reverse transcriptase inhibitor atevirdine. Bioorg. Med. Chem. Lett., 1995, 5, 1875-1880
33. Islam, I.; Hinshaw, R.R.; Chong, K.T.; Kato, A.; Borchardt, R.T.; Fisher, J.F. Synthesis and antiviral activity of [2-[[4-[3-[(1-methylethyl)amino]-2- pyridyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl] (BHAP) acylsphingosine HIV reverse transcriptase inhibitors. Bioorg. Chem., 1995, 23, 499-511.
34. Romero, D.L.; Olmsted, R.A.; Poel, T.J.; Morge, R.A.; Biles, C.; Keiser, B.J.; Kopta, L.A.; Friis, J.M.; Hosley, J.D.; Stefanski, K.J.; Wishka, D.G.; Evans, D.B.; Morris, J.; Stehle, R.G.; Sharma, S.K.; Yagi, Y.; Voorman, R.L.; Adams, W.J.; Tarpley, W.G.; Thomas, R.C. Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl) piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 1996, 39, 3769-3789
35. Genin, M.J.; Poel, T.J.; Yagi, Y.; Biles, C.; Althaus, I.; Keiser, B.J.; Kopta, L.A.; Friis, J.M.; Reusser, F.; Adams, W.J.; Olmsted, R.A.; Voorman, R.L.; Thomas, R.C.; Romero, D.L. Synthesis and bioactivity of novel bis (heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs. J. Med. Chem., 1996, 39, 5267-5275
36. Genin, M.J.; Poel, T.J.; May, P.D.; Kopta, L.A.; Yagi, Y.; Olmsted, R.A.; Friis, J.M.; Voorman, R.L.; Adams, W.J.; Thomas, R.C.; Romero, D.L. Synthesis and structure-activity relationships of the (alkylamino)piperidine-containing BHAP class of nonnucleoside reverse transcriptase inhibitors: effect of 3-alkylpyridine ring substitution. J. Med. Chem., 1999, 42, 4140-4149
37. Guillaumel, J.; Grierson, D.S.; Monneret, C. Synthesis of bisheteroaryl piperazine derivatives as potential reverse transcriptase inhibitors. J. Heterocycl Chem., 2001, 38, 985-988
38. Groopman, J.E. Treatment of AIDS with combination of antiretroviral agents: a summary. Am. J. Med., 1991, 90, 27S-30S.
39. Dueweke, T.J.; Poppe, S.M.; Romero, D.L.; Swaney, S.M.; So, A.G.; Downey, K.M.; Althaus, I.W.; Reusser, F.; Busso, M.; Resnick, L.; Mayers, D.L.; Lane, J.; Aristoff, P.A.; Thomas, R.C.; Tarpley, W.G. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother., 1993, 37, 1127-1131
40. Balzarini, J.; Perez-Perez, M.J.; Velazquez, S.; San-Felix, A.; Camarasa, M.J.; De Clercq, E. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc. Natl. Acad. Sci. USA, 1995, 92, 5470-5474
41. Vasudevachari, M.B.; Battista, C.; Lane, H.C.; Psallidopoulos, M.C.; Zhao, B.; Cook, J.; Palmer, J.R.; Romero, D.L.; Tarpley, W.G.; Salzman, N.P. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology, 1992, 190, 269-277